Project Grant R01AI171046
Award Date
8/20/24
Completion Date
6/30/28
Dollars Obligated
$1.4M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $233,250 to the University of North Carolina at Chapel Hill to perform key proof-of-concept research on a novel bacteriophage-based delivery platform for microbiome engineering. The goal is to develop and characterize self-circulating non-replicative phage vectors (SCNRPVs) capable of safely and efficiently transducing...
The University of Colorado-Denver was awarded a $2,178,000 Project Grant (R56AI186400) from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant will support the development of a "tunable nanophage platform" for rapidly designing, screening, and formulating multi-antigen vaccine candidates against emerging infectious diseases, including SARS-CoV-2 variants and pre-emergent SARS-like...
This $948,482 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research into the molecular mechanisms of the YbtPQ bacterial importer, a novel type of ATP-binding cassette (ABC) transporter found in uropathogenic E. coli. The primary goals are to define the substrate selectivity and inhibitory mechanisms of YbtPQ, as well as understand its unique structural motifs. Researchers at the University of...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $222,852 to support research into the regulation of virulence factors in the pathogenic bacterium Clostridioides difficile. The primary objective is to identify and annotate Rho, NusA, and NusG dependent transcriptional terminators in C. difficile to understand how these regulatory factors influence the...
This $907,800 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a universal bacterial genome editing platform based on phage recombinases. The University of Rochester is leading this research to create a broadly-functioning recombineering system that can edit the genomes of diverse bacterial species, including clinically-relevant pathogens. Key aspects...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), provides $256,995.00 to Tufts University School of Medicine to develop a generalizable strategy for linking quantitative measures of pathogen traits, such as fitness and iron starvation, to host cell mutations using optical sequencing. The project aims to overcome limitations in current approaches for evaluating...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $152,656 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Colorado-Denver. The grant, titled "Synaptopodin and Its Role in Shigella flexneri Intercellular Spread," will fund research to investigate the molecular mechanisms by which the protein synaptopodin promotes the ability of the Shigella bacteria to spread between cells, a critical process for...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) provides $422,931 to characterize the role of specialized microbial metabolites in mediating interactions within the human microbiome. The award aims to integrate cheminformatics analysis of metabolomics data with in vitro model systems to elucidate novel chemistry that influences the structure and function of the microbiome, including...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $195,625 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of Colorado Boulder. The grant supports research to structurally and functionally characterize phosphoethanolamine (PEtN) transferases, enzymes responsible for conferring resistance to cationic antimicrobial peptides (CAMPs) and the antibiotic colistin in multidrug-resistant Gram-negative...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $390,000 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Colorado-Denver. The 5-year grant, which commenced on May 2, 2025, supports research to investigate the molecular basis of how the bacterial pathogen Staphylococcus aureus uses its unique serine protease-like (Spl) enzymes, particularly the Spl B variant, to manipulate host cell processes during infection....